Homburger advised UBS Group on its issuance of USD 3.25 bn fixed rate/floating rate callable senior notes under its Senior Debt Programme. Governed by Swiss law, the notes have been provisionally admitted to trading on the SIX Swiss Exchange, and an application has been submitted for their definitive admission to trading and listing. The Homburger […]
Advestra advised Novartis, as the Basel-based pharma multinational placed notes in the aggregate principal amount of USD 6.0 billion. The issuance featured seven tranches of which six referring to fixed rate notes and one to floating
Niederer Kraft Frey advised CoinShares, a digital asset investment firm with over USD 9.5 billion in AUM, on the listing of its physically-backed Toncoin exchange-traded product (ETP) on the SIX Swiss Exchange in Zurich. The company
Homburger advised Siegfried Holding in connection with the company’s issuance of CHF 300 m 1.3% bonds, to be listed on the SIX Swiss Exchange. Zürcher Kantonalbank and Commerzbank Aktiengesellschaft served as managers on
Homburger advised Sonova Holding in connection with the company’s issuance of CHF 150 m bonds, listed on the SIX Swiss Exchange. Zürcher Kantonalbank and Deutsche Bank (Zurich Branch) served as managers on the
Advestra advised Matterhorn Telecom, the parent company of Swiss telecommunications provider Salt Mobile, in connection with the financing in support of the company’s acquisition of a controlling interest in Monaco Telecom. The financing in
Nexthink, a DEX management specialist backed by Permira, Highland, Index and Auriga, signed a definitive agreement to receive a majority investment from globally active tech investor Vista Equity Partners. The deal values the company at
EQT, as part of a consortium of sellers, completed the sale of 8.4 % of Galderma’s share capital via an accelerated bookbuilding process. The consortium in question further includes Sunshine SwissCo, the Abu Dhabi Investment Authority (
Pestalozzi advised Groupe Bader on the public takeover offer for all publicly held shares of Zwahlen et Mayr. The context Headquartered in Aigle and listed on SIX Swiss Exchange under the ticker symbol “ZWM”, Zwahlen
Homburger advised ADC Therapeutics , a commercial-stage biotechnology company with headquarters in Switzerland, on its USD 60 m private placement of common shares and pre-funded warrants. TCGX led the operation, with further participation from Redmile Group and
